ES2277911T3 - Derivados de glicosaminoglicanos dotados con actividad antiangiogenica y desprovistos de efecto anticoagulante. - Google Patents

Derivados de glicosaminoglicanos dotados con actividad antiangiogenica y desprovistos de efecto anticoagulante. Download PDF

Info

Publication number
ES2277911T3
ES2277911T3 ES01906098T ES01906098T ES2277911T3 ES 2277911 T3 ES2277911 T3 ES 2277911T3 ES 01906098 T ES01906098 T ES 01906098T ES 01906098 T ES01906098 T ES 01906098T ES 2277911 T3 ES2277911 T3 ES 2277911T3
Authority
ES
Spain
Prior art keywords
heparin
desulphated
uronic
desulphation
percentage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01906098T
Other languages
English (en)
Spanish (es)
Inventor
Benito Istituto Scientifico Di Chimica Casu
Giangiacomo Istituto Scientifico di Chim. TORRI
Anna Maria Istituto Scientifico di Chim. NAGGI
Giuseppe Sigma-Tau Industrie Farmaceut. GIANNINI
Claudio Sigma-Tau Industrie Farmaceutiche PISANO
Sergio Penco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2277911T3 publication Critical patent/ES2277911T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
ES01906098T 2000-01-25 2001-01-24 Derivados de glicosaminoglicanos dotados con actividad antiangiogenica y desprovistos de efecto anticoagulante. Expired - Lifetime ES2277911T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM00A0041 2000-01-25
IT2000RM000041A IT1316986B1 (it) 2000-01-25 2000-01-25 Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.

Publications (1)

Publication Number Publication Date
ES2277911T3 true ES2277911T3 (es) 2007-08-01

Family

ID=11454382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01906098T Expired - Lifetime ES2277911T3 (es) 2000-01-25 2001-01-24 Derivados de glicosaminoglicanos dotados con actividad antiangiogenica y desprovistos de efecto anticoagulante.

Country Status (21)

Country Link
US (4) US20030013682A1 (https=)
EP (1) EP1268558B1 (https=)
JP (1) JP5371167B2 (https=)
KR (1) KR100812406B1 (https=)
CN (1) CN100540570C (https=)
AT (1) ATE348115T1 (https=)
AU (1) AU782632B2 (https=)
BR (1) BR0107696A (https=)
CA (1) CA2397964C (https=)
CY (1) CY1108001T1 (https=)
CZ (1) CZ303030B6 (https=)
DE (1) DE60125154T2 (https=)
DK (1) DK1268558T3 (https=)
ES (1) ES2277911T3 (https=)
HU (1) HU229509B1 (https=)
IT (1) IT1316986B1 (https=)
MX (1) MXPA02007195A (https=)
PL (1) PL209479B1 (https=)
PT (1) PT1268558E (https=)
SK (1) SK287566B6 (https=)
WO (1) WO2001055221A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
AU2008202261B2 (en) * 2001-09-12 2011-07-28 Leadiant Biosciences S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
SK288335B6 (sk) * 2001-09-12 2016-02-02 Sigma-Tau Research Switzerland S.A. Čiastočne alebo úplne N-desulfatovaný, N-reacetylovaný heparín, spôsob jeho prípravy, jeho použitie na prípravu liečiva s inhibičným účinkom na heparanázu, s antiangiogénnym a protizápalovým účinkom a farmaceutický prostriedok s jeho obsahom
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
EP2207811B1 (en) * 2007-11-02 2017-01-04 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
BR112012026542A2 (pt) 2010-04-16 2016-07-12 Momenta Pharmaceuticals Inc abordagem seletiva de tecido
US8431826B2 (en) 2010-05-14 2013-04-30 James Robert Howard Capacitive power and ground plane structure utilizing fractal elements for the reduction of radiated emissions
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104144950B (zh) 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
US9507912B2 (en) 2012-08-31 2016-11-29 Nuvectra Corporation Method and system of simulating a pulse generator on a clinician programmer
DK2900061T3 (da) 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
JP6132302B2 (ja) * 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
JP2016520613A (ja) 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
ITLO20130005A1 (it) 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
CN103724458B (zh) * 2014-01-17 2016-03-30 福州大学 含n-非取代葡萄糖胺肝素六糖的制备及其纯化
BR112017018869A2 (pt) 2015-03-06 2018-04-17 Leadiant Biosciences S.A roneparstat e roneparstat para o uso, kit de partes e kit de partes para o uso, composição farmacêutica, método para tratar um mamífero e método para inibição, tratamento, e/ou prevenção de mieloma múltiplo, mieloma de células plasmáticas, mieloma recorrente, refratário ou recidivante em um sujeito
JP2016014148A (ja) * 2015-09-10 2016-01-28 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
CN107177015A (zh) * 2016-03-11 2017-09-19 梁颖 一种重乙酰化肝素修饰物及其制备方法和应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107200A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
WO2019149179A1 (zh) * 2018-02-02 2019-08-08 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
CN114901702B (zh) * 2019-12-27 2024-01-09 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IL79255A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH05157344A (ja) * 1991-12-09 1993-06-22 Mitsubishi Heavy Ind Ltd 空気調和機の吹出口
JPH0512822A (ja) 1991-12-16 1993-01-22 Seiko Epson Corp カートリツジ
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
IT1264709B1 (it) 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
AU2435795A (en) * 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
ATE203534T1 (de) * 1996-01-15 2001-08-15 Janssen Pharmaceutica Nv Angiogenesis hemmende pyridazinamine
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
IT1296581B1 (it) * 1997-11-28 1999-07-14 Istituto Scient Di Chimica E B Materiali polimerici non trombogenici e ad esaltata compatibilita' con fluidi e tessuti organici
IT1296998B1 (it) * 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Also Published As

Publication number Publication date
CZ303030B6 (cs) 2012-03-07
ATE348115T1 (de) 2007-01-15
AU782632B2 (en) 2005-08-18
HU229509B1 (en) 2014-01-28
SK287566B6 (sk) 2011-02-04
JP5371167B2 (ja) 2013-12-18
EP1268558A1 (en) 2003-01-02
KR100812406B1 (ko) 2008-03-11
PL357209A1 (en) 2004-07-26
DE60125154D1 (de) 2007-01-25
US20100298263A1 (en) 2010-11-25
HUP0204196A2 (hu) 2003-03-28
CA2397964C (en) 2010-10-12
AU3406401A (en) 2001-08-07
CN100540570C (zh) 2009-09-16
CZ20022308A3 (cs) 2003-01-15
BR0107696A (pt) 2002-10-15
CY1108001T1 (el) 2013-09-04
US7790700B2 (en) 2010-09-07
US8222231B2 (en) 2012-07-17
US20050222084A1 (en) 2005-10-06
CN1396930A (zh) 2003-02-12
PT1268558E (pt) 2007-02-28
WO2001055221A1 (en) 2001-08-02
EP1268558B1 (en) 2006-12-13
SK10672002A3 (sk) 2002-12-03
DE60125154T2 (de) 2007-10-25
JP2003523460A (ja) 2003-08-05
IT1316986B1 (it) 2003-05-26
ITRM20000041A1 (it) 2001-07-25
HUP0204196A3 (en) 2003-05-28
HK1051867A1 (zh) 2003-08-22
PL209479B1 (pl) 2011-09-30
ITRM20000041A0 (it) 2000-01-25
KR20020080381A (ko) 2002-10-23
CA2397964A1 (en) 2001-08-02
US20050107331A1 (en) 2005-05-19
US20030013682A1 (en) 2003-01-16
MXPA02007195A (es) 2003-01-28
DK1268558T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
ES2277911T3 (es) Derivados de glicosaminoglicanos dotados con actividad antiangiogenica y desprovistos de efecto anticoagulante.
JP5816342B2 (ja) 非抗凝固性多糖組成物
ES2567079T3 (es) Composiciones de polisacáridos que no son anticoagulantes
ES2367778T3 (es) Derivados de glucosaminoglucanos parcialmente desulfatados como inhibidores de heparanasa, provistos de actividad antiangiogénica y desprovistos de efecto anticoagulante.
US8071569B2 (en) Oxidized heparin fractions and their use in inhibiting angiogenesis
Raman et al. Sulfation patterns determine cellular internalization of heparin-like polysaccharides
WO2005110438A2 (en) Methods and products related to the intracellular delivery of polysaccharides
JP2013525306A (ja) 前駆細胞動員を伴う疾患の治療および予防のための多糖組成物および使用方法
Mardhekar et al. Sulfation of Heparan and Chondroitin Sulfate Ligands Enables Cell‐Specific Homing of Nanoprobes
ES2458818T3 (es) Métodos para evaluar la actividad de una composición de polisacárido
Poggi et al. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide
US20020013264A1 (en) Neoglycan anticancer agents and uses thereof
ITMI20010779A1 (it) Uso di polisaccaridi batterici solfati atti all'inibizione dell'angiogenesi
HK1051867B (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
Park et al. Molecular Targeting of VEGF with a Suramin Fragment–DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins. Biomolecules 2021, 11, 46
Nifantiev Chondroitin Sulfate and Fucosylated Chondroitin Sulfate as Stimulators of Hematopoiesis in Cyclophosphamide-Induced Mice
AU2008202261A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect